MarketCapExport financials
Syneos Health (SYNH)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Syneos Health Financial Ratios 2022-2011 | SYNH
Brief overview of Syneos Health's market valuation
Ratios are assessed across five available annual reports in the 2016–2021 interval.
The current valuation set is P/E 40.06x (median 40.17x), EV/EBITDA 7.06x (median 22.11x), P/S 1.8x (median 1.36x). The multiple basket looks neutral against its history, differing from median levels by roughly +14.8%.
Earnings yield calculated as 1/P/E is about 2.5%, showing current profit per unit of share price.
Returns on assets and capital are represented by ROE 7.6%, ROA 3.3%, ROCE 11.5%. Business quality is below comfortable levels on current returns. Better margins or turnover are needed.
Price, earnings and growth produce a PEG of 2.05x. A high value reduces the cushion if growth slows.
The cash conversion cycle shortened from 48.7 days to -10 days, or 58.6 days. Working capital returns faster.
Overall picture
Syneos Health trades near its familiar ratio range. A new earnings or profitability trend is needed to change the view.
Annual Financial Ratios Syneos Health
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
- | 40.1 | 40.2 | 48.4 | 217.4 | -20.7 | 25.4 | 20.8 | -52.9 | - | - | - |
P/S |
- | 1.8 | 1.8 | 1.4 | 1.2 | 1.1 | 1.8 | 1.7 | 1.1 | - | - | - |
EPS |
2.6 | 2.3 | 1.9 | 1.3 | 0.2 | -1.9 | 2.1 | 2.0 | -0.5 | -0.8 | -1.1 | - |
EV (Enterprise Value) |
4.59 B | 14.1 B | 12.3 B | 10.6 B | 9.52 B | 6.81 B | 3.75 B | 3.35 B | 1.96 B | 860 M | 859 M | - |
EBITDA per Share |
6.32 | 6.02 | 4.95 | 4.63 | 4.2 | 2.02 | 3.97 | 3.6 | 2.22 | 1.73 | 0.79 | - |
EV/EBITDA |
7.1 | 22.6 | 23.8 | 22.1 | 21.9 | 45.1 | 17.5 | 16.1 | 16.6 | 9.6 | 20.8 | - |
PEG |
- | 2.05 | 2.33 | 1.71 | 6.81 | -0.61 | 8.32 | 0.04 | 0.11 | - | - | - |
P/B |
- | 2.8 | 2.4 | 2.1 | 1.8 | 1.0 | 9.5 | 11.2 | 3.2 | - | - | - |
P/CF |
- | 20.9 | 18.2 | 20.0 | 17.4 | 14.5 | 26.2 | 11.9 | 9.4 | - | - | - |
ROE % |
7.63 | 6.88 | 5.95 | 4.33 | 0.85 | -4.58 | 37.36 | 53.83 | -5.98 | -15.04 | -18.66 | - |
ROA % |
3.25 | 2.85 | 2.39 | 1.76 | 0.33 | -1.90 | 8.74 | 9.66 | -1.89 | -3.37 | -4.70 | - |
ROCE % |
11.54 | 11.41 | 4.72 | 4.00 | 2.78 | -0.47 | 18.91 | 20.68 | 7.36 | 3.44 | -3.96 | - |
Current Ratio |
1.7 | 1.7 | 1.7 | 1.7 | 1.6 | 1.7 | 1.3 | 1.2 | 1.5 | 1.3 | 1.3 | - |
DSO |
- | - | 32.3 | 59.0 | 57.0 | 58.4 | 41.9 | 37.6 | 40.2 | 23.8 | - | - |
DPO |
10.0 | 10.1 | 13.4 | 11.8 | 8.4 | 10.4 | 7.0 | 6.9 | 5.4 | 2.3 | - | - |
Operating Cycle |
- | - | 32.3 | 59.0 | 57.0 | 58.4 | 41.9 | 37.6 | 40.2 | 23.8 | - | - |
Cash Conversion Cycle |
-10.0 | -10.1 | 18.9 | 47.2 | 48.7 | 47.9 | 34.9 | 30.7 | 34.8 | 21.5 | - | - |
All numbers in USD currency
Quarterly Financial Ratios Syneos Health
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
0.01 | -0.7 | - | 0.85 | 0.76 | 0.45 | - | 0.76 | 0.4 | 0.37 | - | 0.61 | 0.04 | 0.32 | 0.88 | 0.57 | 0.11 | -0.29 | 0.44 | -0.1 | 0.13 | -0.24 | -0.14 | -1.7 | 0.06 | 0.39 | 0.7 | 0.5 | 0.56 | 0.32 | 0.55 | 0.67 | 0.4 | 0.41 | -0.92 | 0.24 | 0.29 | -0.03 | -0.25 | -0.02 | -0.21 | -0.32 | - | - | - | - | - | - | - | - |
EBITDA per Share |
1.57 | 0.21 | - | 2.95 | 2.34 | 1.31 | - | 2.75 | 1.92 | 1.14 | - | 2.55 | 1.41 | 1.01 | 0.8 | 2.43 | 1.74 | 0.85 | 0.77 | 2.36 | 1.62 | 0.75 | 0.14 | 0.09 | 0.48 | 0.93 | 0.81 | 1 | 1 | 0.87 | 0.74 | 1.03 | 0.86 | 0.76 | 0.3 | 0.71 | 0.37 | 0.56 | 0.11 | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
2.86 | 4.24 | 6.33 | 8.69 | 7.38 | 6.25 | 4.85 | 6.89 | 4.67 | 4.50 | 3.31 | 6.31 | 6.32 | 6.59 | 4.40 | 3.00 | 0.57 | 0.66 | 0.87 | -1.23 | -5.75 | -5.27 | 1.89 | 14.82 | 30.15 | 39.72 | 40.31 | 41.97 | 43.43 | 41.22 | 40.49 | 13.70 | 5.00 | 0.59 | -5.98 | 2.01 | 3.90 | -0.40 | -4.70 | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
1.13 | 1.67 | 2.56 | 3.52 | 2.98 | 2.52 | 1.96 | 2.82 | 1.92 | 1.84 | 1.35 | 2.58 | 2.52 | 2.62 | 1.77 | 1.17 | 0.23 | 0.27 | 0.34 | -0.50 | -2.38 | -2.32 | -0.34 | 2.78 | 7.00 | 9.17 | 8.95 | 8.57 | 9.28 | 8.77 | 9.33 | 2.79 | 0.90 | 0.21 | -1.90 | 1.06 | 1.23 | -0.12 | -1.05 | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
7.08 | 8.11 | 9.25 | 12.67 | 11.74 | 10.12 | 7.88 | 11.07 | 8.82 | 7.88 | 6.00 | 8.75 | 7.98 | 8.88 | 8.18 | 8.21 | 7.19 | 6.22 | 5.63 | 3.34 | -1.00 | 0.81 | 10.82 | 24.85 | 42.83 | 53.67 | 56.21 | 59.94 | 58.84 | 57.92 | 52.94 | 39.39 | 31.24 | 20.43 | 16.23 | 15.61 | 2.01 | 3.72 | 4.08 | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
1.8 | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 | 1.6 | 1.7 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.7 | 1.7 | 1.7 | 1.4 | 1.4 | 1.3 | 1.3 | 1.3 | 1.3 | 1.2 | 1.3 | 1.3 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.3 | - | - | - | - | - | - | - | - | - | - | - |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - | - | 30.7 | - | 59.9 | 58.6 | 59.2 | - | 54.8 | 60.0 | 59.2 | 78.2 | 48.1 | 48.0 | 47.7 | - | 56168.9 | 177291.9 | 81332.0 | - | 146259.6 | 39.7 | 41.4 | - | 39.8 | 41.6 | 44.5 | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
12.1 | 11.1 | - | 9.8 | 9.2 | 9.4 | - | 9.6 | 10.2 | 11.0 | - | 11.0 | 11.6 | 12.3 | - | 10.6 | 11.1 | 9.9 | - | 8.8 | 8.4 | 7.0 | - | - | 7.0 | 6.8 | - | 7.7 | 10.2 | 9.1 | - | 5.3 | 5.3 | 6.3 | - | 6.8 | 7.1 | 5.9 | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | 30.7 | - | 59.9 | 58.6 | 59.2 | - | 59.6 | 62.0 | 59.2 | 78.2 | 71.3 | 96.9 | 47.7 | - | 43.0 | 45.9 | 40.8 | - | 41.3 | 42.8 | 42.6 | - | 39.8 | 41.6 | 44.5 | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | -11.1 | - | - | - | -9.4 | - | -9.6 | -10.2 | -11.0 | - | -12.7 | -12.9 | 18.3 | - | 46.3 | 45.1 | 47.1 | - | 49.3 | 51.4 | 50.7 | 78.2 | 71.3 | 78.8 | 34.5 | - | 35.6 | 38.7 | 34.2 | - | 33.1 | 34.5 | 34.6 | - | 33.0 | 34.5 | 38.6 | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Syneos Health, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Diagnostics research industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
CareDx, Inc
CDNA
|
$ 54.31 | 0.32 % | $ 2.89 B |  USA |
 |
Celcuity
CELC
|
$ 79.99 | 0.12 % | $ 3.74 B | USA |
 |
Co-Diagnostics
CODX
|
$ 1.1 | 1.85 % | $ 1.46 M | USA |
 |
Castle Biosciences
CSTL
|
$ 34.88 | 0.09 % | $ 1.01 B | USA |
 |
Danaher Corporation
DHR
|
$ 221.56 | 0.21 % | $ 158 B | USA |
 |
DexCom
DXCM
|
$ 87.73 | 0.21 % | $ 34.2 B | USA |
 |
Fulgent Genetics
FLGT
|
$ 21.27 | 0.51 % | $ 655 M | USA |
 |
Guardant Health
GH
|
$ 176.31 | 0.27 % | $ 22.1 B | USA |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
$ 163.9 | 0.2 % | $ 12.9 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
$ 522.02 | 0.1 % | $ 42 B | USA |
 |
IQVIA Holdings
IQV
|
$ 267.86 | 0.41 % | $ 46 B | USA |
 |
Anixa Biosciences
ANIX
|
$ 2.75 | 3.33 % | $ 89.2 K | USA |
 |
Laboratory Corporation of America Holdings
LH
|
$ 303.98 | 0.09 % | $ 25.3 B | USA |
 |
Lantheus Holdings
LNTH
|
$ 99.97 | 0.01 % | $ 6.75 B | USA |
 |
Medpace Holdings
MEDP
|
$ 617.15 | 0.23 % | $ 17.8 B | USA |
 |
Mettler-Toledo International
MTD
|
$ 1 492.34 | 0.11 % | $ 30.8 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
$ 4.01 | 0.62 % | $ 371 M | USA |
 |
ENDRA Life Sciences
NDRA
|
$ 6.5 | 4.33 % | $ 5.12 M | USA |
 |
NeoGenomics
NEO
|
$ 18.36 | 0.03 % | $ 2.35 B | USA |
 |
Neogen Corporation
NEOG
|
$ 13.57 | 2.72 % | $ 2.95 B | USA |
 |
Natera
NTRA
|
$ 390.79 | 0.41 % | $ 53.4 B | USA |
 |
Biomerica
BMRA
|
$ 2.61 | 0.36 % | $ 7.61 M | USA |
 |
OPKO Health
OPK
|
$ 1.7 | 0.29 % | $ 1.28 B | USA |
 |
RadNet
RDNT
|
$ 73.21 | 0.11 % | $ 5.5 B | USA |
 |
Sotera Health Company
SHC
|
$ 18.29 | 0.45 % | $ 5.19 B | USA |
 |
Neuronetics
STIM
|
$ 2.88 | 0.21 % | $ 190 M | USA |
 |
Trinity Biotech plc
TRIB
|
$ 7.01 | 0.68 % | $ 2.52 B | Irlanda |
 |
Twist Bioscience Corporation
TWST
|
$ 158.47 | 0.93 % | $ 9.48 B | USA |
 |
Biodesix
BDSX
|
$ 29.29 | 4.05 % | $ 221 M | USA |
 |
VolitionRx Limited
VNRX
|
$ 0.25 | 2.99 % | $ 31.4 M |  Singapore |
 |
Waters Corporation
WAT
|
$ 420.57 | 0.52 % | $ 25 B | USA |
 |
Exagen
XGN
|
$ 8.55 | 1.39 % | $ 184 M | USA |
 |
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K |  Israel |
 |
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M |  Britain |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | USA |
 |
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | USA |
 |
Quotient Limited
QTNT
|
- | -11.32 % | $ 1.1 M | Schweiz |
 |
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | USA |
 |
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | USA |
 |
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | USA |
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
$ 1.7 | 0.55 % | $ 9.26 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
$ 15.08 | 11.68 % | $ 162 M |  China |
 |
Bioventus
BVS
|
$ 13.61 | 2.55 % | $ 907 M | USA |
 |
Brainsway Ltd.
BWAY
|
$ 13.45 | 0.88 % | $ 457 M | Israel |